Anyone hoping for an upheaval at the top of pharma’s drug sales charts next year will have to keep waiting. AbbVie’s $20 billion behemoth Humira will continue to dominate in 2018, with Celgene’s Revlimid a distant second. Among the stalwarts: Merck’s immunotherapy Keytruda.
More: 2018's best-sellers? AbbVie's Humira, obviously, but newcomers are on their way